Appointment booking for Dr. Charles Betts, MD is currently not available.Dr. Charles Betts, MD has not yet fully activated their profile on DiabetesIQ.
Dr. Charles Betts, MD (he/him) is a Nephrologist in Kittanning, PA with over 19 years of experience. What is your opinion of Dr. Charles Betts, MD? Rate this provider below so other people can make informed decision.
Gender
Male
Experience
Over 19 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Charles Betts, MD has received over $825 which includes payments from the following companies:
$125.27 from Baxter Healthcare
$90.58 from AMAG Pharmaceuticals, Inc.
$81.05 from Amgen Inc.
$70.56 from NxStage Medical, Inc.
$68.64 from Questcor Pharmaceuticals
$68.45 from AKEBIA THERAPEUTICS INC
$51.70 from Cumberland Pharmaceuticals, Inc.
$35.54 from AstraZeneca Pharmaceuticals LP
$34.05 from Genentech USA, Inc.
$32.74 from Mallinckrodt LLC
$31.02 from Fresenius USA Marketing, Inc.
$28.39 from Takeda Pharmaceuticals America, Inc.
$28.07 from Relypsa, Inc.
$20.77 from sanofi-aventis U.S. LLC
$20.65 from Alexion Pharmaceuticals, Inc.
$13.12 from Mallinckrodt Enterprises LLC
$12.91 from Beckman Coulter, Inc.
$11.35 from GENZYME CORPORATION
$0.54 from Retrophin, Inc.
Payments received by Dr. Charles Betts, MD were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!